Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN) , protocol number BEGIN NCT04509050

    This two-part observational study will look at the effects of CFTR modulators on growth in infants and young children with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      0 Years to 6 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      3 Years

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Australia & New Zealand

    Study to evaluate ARO-ENaC in adults with cystic fibrosis (AROENaC-1001) , protocol number ARO-ENaC NCT04375514

    This study will evaluate the safety and tolerability of ARO-ENaC, a drug intended to thin airway surface liquid. Multiple doses of the drug will be tested in adults with cystic fibrosis to find the optimal dose.

    • Age:

      18 Years to 55 Years

    • Mutation(s):

      No mutation requirements

    • FEV1% Predicted:

      between 40% and 99%

    • Number of Visits:

      12

    • Length of Participation:

      113 days

    Contact us about this clinical Trial >
  • Anti-InflammatoryNot yet recruiting Location: Brisbane

    A double blind, randomized, placebo controlled, cross-over trial investigating the effect of High Amylose Maize Starch (HAMS) supplementation on fecal microbiological and inflammatory outcomes in individuals with Cystic Fibrosis and Healthy Volunteers , protocol number ACTRN12618000283279

    Cystic Fibrosis (CF) is associated with a significant increase in gut dysbiosis. Exposure to multiple courses of antibiotics as well as an inherently inflammatory gut contributes to this. We have shown that there are significant differences between the CF gut and healthy volunteers in these respects. High amylose maize starch (HAMS) is a pre-biotic food stuff produced in such a way as to encourage the production of beneficial, anti-inflammatory compounds. In laboratory culture, we have shown that HAMS increases the production of these compounds. What is not clear however is whether this laboratory data translates to a clinical benefit. This study will attempt to understand the impact of HAMS supplementation on the bacteria in the gut and the ability of the gut to make anti-inflammatory compounds, in adult patients with CF as well as in healthy control subjects.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Nutritional-GIEnrolling Location: Ohio, USA

    OPTION 2: Study of AzurRX MS1819 in enteric capsules in adults with cystic fibrosis and exocrine pancreatic insufficiency (AzurRX AZ-CF2002) , protocol number NCT04375878

    This study will look at the safety and effectiveness of the drug MS1819 in enteric capsules as a pancreatic enzyme replacement therapy (PERT).

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      30% or greater

    • Number of Visits:

      10

    • Length of Participation:

      8 weeks

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Multiple care centres across the US

    SIMPLIFY: Study to evaluate stopping inhaled hypertonic saline or dornase alfa in people with CF who are taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor , protocol number SIMPLIFY-IP-19 NCT04378153

    This study will test the effects and safety of stopping inhaled hypertonic saline or dornase alfa (Pulmozyme®) in teens and adults with CF who are also taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (Trikafta®). Trikafta® is intended to help CFTR function closer to normal, resulting in better clearance of mucus from the lungs. Inhaled hypertonic saline and dornase alfa are intended to thin airway surface liquid and improve clearance of mucus from the lungs. They are considered to be relatively burdensome therapies, so this study will look at the impact of stopping them in people who are also taking Trikafta®.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      60% or greater

    • Number of Visits:

      4

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryActive, not recruiting Location: Montreal, Toronto and Vancouver

    Phase 1b study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa. , protocol number Calithera CX-280-202 NCT04279769

    Patients will receive either CB-280 twice daily orally for 14 days or a placebo

    • Age:

      18 Years and older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      40% and 90%

    • Number of Visits:

      Not specified

    • Length of Participation:

      2 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceRecruiting Location: Sir Charles Gairdner Hospital, Perth, WA

    Does the MetaNeb®, a new airway clearance device, change lung function in adults with cystic fibrosis when they are hospitalised for a lung infection? , protocol number ACTRN12619001681145

    This project will look at the effects of twice daily treatment using a new airway clearance device called the MetaNeb®, on lung function, secretion clearance and CF related symptoms compared to twice daily treatment using ACT in adults with CF who are hospitalised with a respiratory exacerbation. We hypothesise that in adults with CF, hospitalised with a respiratory exacerbation, twice daily MetaNeb® treatment, compared with usual ACT, will produce greater improvements in lung function, secretion clearance, health-related quality of life (HRQoL) and respiratory signs and symptoms. If this device is shown to be more effective than the commonly used techniques, this would be of great clinical significance as it will assist in guiding clinical use of the device throughout CF centres in Australia and internationally.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Queensland Children's Hospital, Brisbane

    Implementing a comprehensive adherence protocol for children and adolescents living with cystic fibrosis - an implementation study , protocol number ACTRN12619001730190

    The primary aim of this project is to evaluate the feasibility, acceptability and appropriateness of implementing a comprehensive adherence protocol into the Queensland Children's Hospital Cystic Fibrosis clinic.

    • Age:

      8 Years and 18

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Royal Prince Alfred Hospital, NSW

    Cystic Fibrosis Telehealth Virtual Clinic Initiative , protocol number ACTRN12620000084987

    This study will evaluate an updated health care delivery model for patients with cystic fibrosis by incorporating virtual health/telehealth clinics. For patients in the telehealth arm, clinic visits may occur at home, work or at their local GP practice. This will replace in-hospital clinic visits. Patients in this arm however will need to attend at least one in-hospital clinic visit over a 12 months period. Spirometry will be performed at home using a portable spirometer. Patient satisfaction and well-being questionnaires will need to be completed at baseline, 6 and 12 months.

    • Age:

      16 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      1

    • Length of Participation:

      12 months

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Vancouver, Calgary, Toronto

    A phase 3 study on the use of prednisone in cystic fibrosis pulmonary exacerbations (PIPE) , protocol number PIPE NCT03070522

    To evaluate the effectiveness of prednisone as an adjunctive treatment for patients who do not respond to regular IV antibiotics

    • Age:

      6+

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      3 years

    Contact us about this clinical Trial >
  • Displaying results 31-40 (of 225)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|